Treatment of mucosal leishmaniasis with a lipid formulation of amphotericin B.
Amato
Valdir Sabbaga
VS
Tuon
Felipe Francisco
FF
Campos
Aleia
A
Bacha
Helio Arthur
HA
Nicodemo
Antonio Carlos
AC
Amato Neto
Vicente
V
Shikanai-Yasuda
Maria Aparecida
MA
D000368:Aged; D000666:Amphotericin B / Q000009:adverse effects / Q000627:therapeutic use*; D000981:Antiprotozoal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010713:Phosphatidylcholines / Q000009:adverse effects / Q000627:therapeutic use*; D010715:Phosphatidylglycerols / Q000009:adverse effects / Q000627:therapeutic use*; D010865:Pilot Projects
D000981:Antiprotozoal Agents; D004338:Drug Combinations; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; C068538:liposomal amphotericin B; D000666:Amphotericin B